Patents by Inventor Jean-Marc Cavaillon

Jean-Marc Cavaillon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPTIMAL COMBINATION OF EARLY BIOMARKERS FOR INFECTION AND SEPSIS DIAGNOSIS IN EMERGENCY DEPARTMENT
    Publication number: 20240036060
    Abstract: The present invention allows a rapid and early diagnosis of bacterial or viral infection. Such a diagnosis is highly desired among patients admitted in emergency department to allow the initiation of the appropriate treatment. Although no biomarker alone can offer an appropriate diagnosis with sufficient sensitivity and specificity, the present invention defines optimal combinations of biomarkers allowing the diagnosis of infection.
    Type: Application
    Filed: October 11, 2021
    Publication date: February 1, 2024
    Inventors: Jean-Marc CAVAILLON, Laetitia VELLY, Pierre HAUSFATER, Catherine FITTING, Stevenn VOLANT, Florian SALIPANTE, Lionel VALERA, Jeannette FAREH
  • Inflammation-inhibitory serum factors and uses thereof
    Patent number: 8821851
    Abstract: Disclosed are methods of purifying compounds that reduce or prevent an inflammatory response in a mammal, use of such compounds in treating a mammal having or being at risk of developing inflammation, as well as serum containing such purified compounds. Also disclosed are animal models that are more representative of humans in the study of inflammatory responses or as screening tools for discovering or developing new therapeutics or lead candidate compounds for inhibition of an inflammatory response.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: September 2, 2014
    Assignees: The General Hospital Corporation, Institut Pasteur
    Inventors: H. Shaw Warren, Jean-Marc Cavaillon
  • Inflammation-Inhibitory Serum Factors and Uses Thereof
    Publication number: 20090175797
    Abstract: Disclosed are methods of purifying compounds that reduce or prevent an inflammatory response in a mammal, use of such compounds in treating a mammal having or being at risk of developing inflammation, as well as serum containing such purified compounds. Also disclosed are animal models that are more representative of humans in the study of inflammatory responses or as screening tools for discovering or developing new therapeutics or lead candidate compounds for inhibition of an inflammatory response.
    Type: Application
    Filed: March 22, 2007
    Publication date: July 9, 2009
    Applicant: THE GERNERAL HOSPITAL CORPORATION
    Inventors: H. Shaw Warren, Jean-Marc Cavaillon